Work

SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML

Year: 2015

Type: article

Source: Blood

DOI: 10.1182/blood.v126.23.454.454

Authors: Amir T. Fathi, Harry P Erba, Jeffrey E Lancet, Eytan M Stein, Roland B. Walter, Daniel J. DeAngelo, Stefan Faderl, Anand P Jillella, Farhad Ravandi, Anjali S. Advani, Dale Bixby, Tibor J. Kovacsovics, Megan M. O'Meara, Dana A. Kennedy, Anthony S. Stein

Institutions: Harvard University, Massachusetts General Hospital, University of Alabama at Birmingham, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Hackensack University Medical Center, Winship Cancer Institute, The University of Texas MD Anderson Cancer Center, Cleveland Clinic, University of Michigan, U-M Rogel Cancer Center, University of Utah, Huntsman Cancer Institute, Seagen (United States), City Of Hope National Medical Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979458152

FWCI: 5.203

Cites:

Cited by: 24

Related to: 10